Premium
B acillus amyloliquefaciens as prophylactic treatment for C lostridium difficile ‐associated disease in a mouse model
Author(s) -
Geeraerts S,
Ducatelle R,
Haesebrouck F,
Van Immerseel F
Publication year - 2015
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.12957
Subject(s) - bacillus amyloliquefaciens , saccharomyces boulardii , medicine , in vivo , clostridium difficile , microbiology and biotechnology , gastroenterology , pharmacology , antibiotics , bacteria , biology , probiotic , genetics
Background and Aim Probiotics might offer an attractive alternative for standard antibiotic therapy to treat C lostridium difficile infections ( CDI ). We specifically selected a B acillus amyloliquefaciens strain for its high in vitro antibacterial activity against C . difficile and tested its efficacy to prevent CDI in a mouse model. Methods B . amyloliquefaciens supernatant was tested against a large collection of C . difficile strains using an agar well diffusion test. B . amyloliquefaciens was orally administered to C57BL /6 mice in which CDI was induced using C . difficile VPI 10463, and its effect was compared with control mice receiving no treatment and mice receiving S accharomyces boulardii . Mice were followed up daily for signs of disease including weight loss. At necropsy, the colon was collected and subjected to histopathological analysis. C . difficile toxin A / B levels and colon weight/length and colon/body weight ratios were calculated. Results B . amyloliquefaciens supernatant was able to inhibit the growth of all C . difficile strains. Results of the in vivo trial indicated a significant weight loss for untreated and S . boulardii ‐treated mice as compared to B . amyloliquefaciens ‐treated mice. C . difficile toxin A and B levels were significantly higher for untreated and S . boulardii ‐treated mice than B . amyloliquefaciens ‐treated mice. A significantly lower degree of colon damage was detected for B . amyloliquefaciens ‐treated mice as compared to untreated and S . boulardii ‐treated mice, based on histopathological analysis, colon weight/length and colon/body weight ratios. Conclusion Administration of B . amyloliquefaciens was successful in preventing CDI in a mouse model.